Emil R Bulatov

List of Publications by Year
in descending order

26 papers	787 citations	471061 17 h-index	610482 24 g-index
26 all docs	26 docs citations	26 times ranked	1312 citing authors

#	Article	IF	Citations
1	Knowns and Unknowns about CAR-T Cell Dysfunction. Cancers, 2022, 14, 1078.	1.7	23
2	Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections. Biomedicines, 2021, 9, 59.	1.4	60
3	Adoptive Immunotherapy beyond CAR T-Cells. Cancers, 2021, 13, 743.	1.7	57
4	Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies. Frontiers in Immunology, 2021, 12, 707734.	2.2	30
5	Design, synthesis and biological evaluation of 2-quinolyl-1,3-tropolone derivatives as new anti-cancer agents. RSC Advances, 2021, 11, 4555-4571.	1.7	11
6	Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy. Frontiers in Oncology, 2020, 10, 1460.	1.3	30
7	Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?. Genes, 2020, 11, 704.	1.0	31
8	Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment. Cancers, 2020, 12, 125.	1.7	50
9	Novel approaches for the rational design of PROTAC linkers. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 381-390.	0.5	17
10	Granulocyte-Macrophage Colony-Stimulating Factor and CAR-T Technology for Solid Tumors in Experiment. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2020, 13, 115-122.	0.1	2
11	The Effect of Macrophage Polarization on Cytokine Release in CAR-T Antitumor Response. Blood, 2020, 136, 22-22.	0.6	1
12	Expression of mutant p53 affects cancer cell sensitivity to topotecan. Annals of Oncology, 2019, 30, v803.	0.6	0
13	Novel Isatin-based activator of p53 transcriptional functions in tumor cells. Molecular Biology Research Communications, 2019, 8, 119-128.	0.2	19
14	Isatin-Schiff base-copper (II) complex induces cell death in p53-positive tumors. Cell Death Discovery, 2018, 4, 103.	2.0	41
15	The biological basis and clinical symptoms of CAR-T therapy-associated toxicites. Cell Death and Disease, 2018, 9, 897.	2.7	90
16	Endonuclease from Gram-Negative Bacteria Serratia marcescens Is as Effective as Pulmozyme in the Hydrolysis of DNA in Sputum. Frontiers in Pharmacology, 2018, 9, 114.	1.6	13
17	Small Molecule Modulators of RING-Type E3 Ligases: MDM and Cullin Families as Targets. Frontiers in Pharmacology, 2018, 9, 450.	1.6	23
18	Promising new therapeutic targets for regulation of inflammation and immunity: RING-type E3 ubiquitin ligases. Immunology Letters, 2018, 202, 44-51.	1.1	20

#	Article	IF	Citations
19	Screening for Immunosuppressive Genes Responsible for Resistance Towards CAR-T Cell Therapy in Cancer Cells. Blood, 2018, 132, 4965-4965.	0.6	0
20	A One-Step Protocol for Chromatographic Purification of Non-recombinant Exogenous Bacterial Enzyme: Nuclease of Serratia marcescens. BioNanoScience, 2016, 6, 335-337.	1.5	1
21	Ubiquitin-Proteasome System: Promising Therapeutic Targets in Autoimmune and Neurodegenerative Diseases. BioNanoScience, 2016, 6, 341-344.	1.5	24
22	Serendipitous SAD Solution for DMSO-Soaked SOCS2-ElonginC-ElonginB Crystals Using Covalently Incorporated Dimethylarsenic: Insights into Substrate Receptor Conformational Flexibility in Cullin RING Ligases. PLoS ONE, 2015, 10, e0131218.	1.1	16
23	Targeting Cullinâ€"RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation. Biochemical Journal, 2015, 467, 365-386.	1.7	168
24	Biophysical Studies on Interactions and Assembly of Full-size E3 Ubiquitin Ligase. Journal of Biological Chemistry, 2015, 290, 4178-4191.	1.6	24
25	Binding and purification of plasmid DNA using multi-layered carbon nanotubes. Journal of Biotechnology, 2011, 152, 102-107.	1.9	18
26	Effect of size and protein environment on electrochemical properties of gold nanoparticles on carbon electrodes. Bioelectrochemistry, 2009, 77, 37-42.	2.4	18